The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Hepatic Impairment, Healthy Volunteers
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
-
Arizona Liver Health, Chandler, Arizona, United States, 85225
Local Institution - 0004, Chandler, Arizona, United States, 85225
Local Institution - 0005, Orlando, Florida, United States, 32809
Orlando Clinical Research Center, Orlando, Florida, United States, 32809
Local Institution - 0006, San Antonio, Texas, United States, 78215
Texas Liver Institute, San Antonio, Texas, United States, 78215
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
Yes
Celgene,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2025-10-11